An expedited process for adding indications to biosimilar product labels and a staged review of 351(k) applications appear to be early items on industry’s wish list for the third iteration of the Biosimilar User Fee Act (BsUFA).
In comments to the US FDA on biologic product competition and innovation, Johnson & Johnson’s Janssen Pharmaceutical Cos....






